MX2022005347A - Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia. - Google Patents

Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia.

Info

Publication number
MX2022005347A
MX2022005347A MX2022005347A MX2022005347A MX2022005347A MX 2022005347 A MX2022005347 A MX 2022005347A MX 2022005347 A MX2022005347 A MX 2022005347A MX 2022005347 A MX2022005347 A MX 2022005347A MX 2022005347 A MX2022005347 A MX 2022005347A
Authority
MX
Mexico
Prior art keywords
treatment
cardiotoxicity
chemotherapy
prevention
iodide compounds
Prior art date
Application number
MX2022005347A
Other languages
English (en)
Inventor
Mark B Roth
Michael L Morrison
Akiko Iwata
Stephen A Hill
Michael Andrew Insko
Original Assignee
Faraday Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faraday Pharmaceuticals Inc filed Critical Faraday Pharmaceuticals Inc
Publication of MX2022005347A publication Critical patent/MX2022005347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de compuestos de yoduro, para tratar y prevenir la caquexia y la cardiotoxicidad que resultan del tratamiento con una terapia antineoplásica.
MX2022005347A 2019-11-04 2020-11-03 Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia. MX2022005347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930244P 2019-11-04 2019-11-04
PCT/US2020/058756 WO2021137932A1 (en) 2019-11-04 2020-11-03 Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity

Publications (1)

Publication Number Publication Date
MX2022005347A true MX2022005347A (es) 2022-10-07

Family

ID=76686690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005347A MX2022005347A (es) 2019-11-04 2020-11-03 Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia.

Country Status (10)

Country Link
US (1) US20220387483A1 (es)
EP (1) EP4054593A1 (es)
JP (1) JP2023500702A (es)
KR (1) KR20220101120A (es)
CN (1) CN114929246A (es)
AU (1) AU2020417997A1 (es)
CA (1) CA3160144A1 (es)
IL (1) IL292688A (es)
MX (1) MX2022005347A (es)
WO (1) WO2021137932A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ721500A (en) 2014-02-10 2022-11-25 Fred Hutchinson Cancer Center Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
SG188161A1 (en) * 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ721500A (en) * 2014-02-10 2022-11-25 Fred Hutchinson Cancer Center Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
US9428470B2 (en) * 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
AU2020417997A1 (en) 2022-06-16
KR20220101120A (ko) 2022-07-19
CN114929246A (zh) 2022-08-19
EP4054593A1 (en) 2022-09-14
WO2021137932A1 (en) 2021-07-08
IL292688A (en) 2022-07-01
US20220387483A1 (en) 2022-12-08
CA3160144A1 (en) 2021-07-08
JP2023500702A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
EP3600281A4 (en) COMBINATION THERAPY FOR TREATING OR PREVENTING TUMORS
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
IL280337A (en) LAG-3 combination therapy for cancer treatment
MX2017009246A (es) Farmaco de combinacion.
MX2020006297A (es) Variantes de cd19.
ZA202206743B (en) Therapy for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
IL281845A (en) Combined treatment for cancer
IL275949A (en) Combined treatment for the treatment of cancer or its prevention
IL284162A (en) Integrated healing for cancer treatment
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
MX2022005347A (es) Uso de compuestos de yoduro para el tratamiento y prevención de la caquexia y cardiotoxicidad asociadas con la quimioterapia.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
IL276074A (en) Combined treatment for the treatment of cancer or its prevention
IL276073A (en) Combined treatment for the treatment of cancer or its prevention